Improving cell therapies through advanced single-cell sequencing technology
Official title: A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies
Funded at Sansimeon, INC · NIH-10822508 · Data updated 2026-11-12
This study is looking at a new way to improve cancer treatments like CAR-T therapy by examining a lot more immune cells from patients, which could help make these therapies work better and be more affordable for everyone.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sansimeon, INC NIH-funded |
| Lab location | 1 site (Fremont, United States) |
| Project start | February 23, 2024 |
| Project end | February 22, 2026 |
| Funding year | 2024 |
| Award (this year) | $399,369 |
| NIH project number | 1R43HG013446-01 |
| Project ID | NIH-10822508 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are undergoing treatment for cancers that may benefit from advanced immunotherapy.
✕Less likely to help
Patients who are not diagnosed with cancer or those who are under 21 years old may not receive any benefit from this research.
What this research studies
This research focuses on enhancing immunotherapies, such as CAR-T cell therapies, by utilizing a novel single-cell sequencing (SC-seq) approach that significantly increases the number of cells analyzed. By mapping a patient's immune response at the single-cell level, the research aims to improve the effectiveness and affordability of these therapies. The proposed method can process over 100 million cells, which is a substantial improvement over current technologies that are limited to 1 million cells per experiment. This advancement could lead to better-targeted treatments and a deeper understanding of immune responses in patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and accessible immunotherapies for patients with various cancers.
How similar studies have gone: Other research has shown promise in using single-cell sequencing for immune profiling, but this specific scalable approach is novel and has not been widely tested.
Where this research is happening
-
Sansimeon, INC
Fremont, United States Active
Researchers
- Principal investigator: Spuhler, Philipp Stefan — Sansimeon, INC
- Study coordinator: Spuhler, Philipp Stefan
Related research
Other NIH-funded projects on the same topics.
-
A fast, scalable platform for decoding tens of millions of cells from patient samples
A new high-throughput system helps scientists study very large numbers of cells from patient blood and tumor samples to improve cancer care.
-
Fast, scalable single-cell testing for blood and tissue samples
This project builds a fast, easy system to read the genes of millions of individual cells from blood and tissue to help cancer patients and researchers spot rare cells and better match treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.